MAY 13, 2020 5:48 PM PDT

Approved Treatment for RET-mutant Cancers

WRITTEN BY: Nouran Amin

A drug was recently approved for treating three types of RET-mutant cancers: 1) non-small cell lung cancer (NSCLC) 2) advanced or metastatic RET-mutant medullary thyroid cancer (MTC) that may require systemic therapy and 3) advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Learn more:

The FDA-approved drug by Eli Lily and Company is Retevmo™ (selpercatinib, 40 mg & 80 mg capsules) which came after findings of a LIBRETTO-001 clinical trial.

"In the clinical trial, we observed that the majority of metastatic lung cancer patients experienced clinically meaningful responses when treated with selpercatinib, including responses in difficult-to-treat brain metastases," said Alexander Drilon, M.D., acting chief of early drug development at Memorial Sloan Kettering Cancer Center and lead investigator for LIBRETTO-001. "The approval of selpercatinib marks an important milestone in the treatment of NSCLC, making RET-driven cancers now specifically targetable in the same manner as cancers with activating EGFR and ALK alterations, across all lines of therapy. I am pleased that patients with these RET-driven cancers have this newly approved option."

Retevmo is an oral prescriptive medication that works as a selective RET kinase inhibitor and may target both tumor cells and healthy cells.

"RET alterations account for the majority of medullary thyroid cancers and a meaningful percentage of other thyroid cancers. For patients living with these cancers, the approval of selpercatinib means they now have a treatment option that selectively and potently inhibits RET," said Lori J. Wirth, M.D., medical director of head and neck cancers, Massachusetts General Hospital Cancer Center. "Based on the published data for this new medicine, as well as my personal experience treating patients, this may be a good treatment option."

Source: Eli Lilly

About the Author
Master's (MA/MS/Other)
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
NOV 25, 2022
Drug Discovery & Development
Leprosy-causing Bacteria Generate Healthy Livers in Armadillos
Leprosy-causing Bacteria Generate Healthy Livers in Armadillos
Bacteria that cause leprosy may be able to regenerate liver cells in adult animals without negative side effects. The co ...
NOV 26, 2022
Neuroscience
A Crucial Enzyme Seems to Switch Off Randomly, Defying Previous Expectations
A Crucial Enzyme Seems to Switch Off Randomly, Defying Previous Expectations
A crucial enzyme in the mammalian brain seems to randomly switch on and off, according to new research reported in Natur ...
DEC 04, 2022
Cannabis Sciences
Increasing Interest in Psychoactive Treatments for Mood Disorders
Increasing Interest in Psychoactive Treatments for Mood Disorders
Findings from various studies presented at the Society for Neuroscience 2022 annual meeting highlighted the need for inn ...
DEC 01, 2022
Drug Discovery & Development
The Impact of AI on Drug Discovery
The Impact of AI on Drug Discovery
Artificial Intelligence, also known as “AI”, has been the talk of the past year. AI performs and responds to ...
JAN 19, 2023
Drug Discovery & Development
Newest Treatment for Rosacea: Encapsulated Benzoyl Peroxide Cream
Newest Treatment for Rosacea: Encapsulated Benzoyl Peroxide Cream
Rosacea is a dermatologic condition affecting the centrofacial region (cheeks, chin, nose, and forehead), resulting ...
JAN 23, 2023
Drug Discovery & Development
New protein discovery holds promise for developing more effective snake anti-venoms
New protein discovery holds promise for developing more effective snake anti-venoms
Venomous snakes, which include cobras, vipers, and rattlesnakes, can pose a significant danger to humans. In the Un ...
Loading Comments...